Anti-Human CD194 (CCR4) (Mogamulizumab) – HRP
Pricing & Details
Antibody DetailsProduct DetailsReactivity Species Human Expression Host HEK-293 FC Effector Activity Active Immunogen Humanization of mouse anti-CCR4 mAb7. Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893876 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Other Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. Antigen Distribution CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). Background Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3 Antigen DetailsProtein PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology . Innate Immunity . Stem Cell References & Citations1. Yamamoto, K. et al. (2010) J Clin Oncol. 28(9):1591-8. 2. Mimura, Y. et al. (2018) Protein Cell 9(1):47-62. 3. Yamano, Y. et al. (2018) N Engl J Med 378 (6), 529-538. Technical Protocols |
Formats Available
Prod No. | Description |
---|---|
LT1000 |
|
LT1005 |
|
LT1002 |
|
LT1001 |
|
LT1006 |
|
LT1007 |
